Company intelligence / Profile preview

PENAO

Sydney, New South Wales, Australia

Ownership: Private
Development stage: Other

Overview

PENAO’s proprietary small molecule (ANT inhibitor) demonstrated safety and encouraging efficacy in a 26-patient Phase 1 clinical trial for advanced solid tumors. It showed dramatic improvements in cellular uptake and anti-tumor activity over GSAO, the earlier gold standard. Larger Phase 1/2 trials are in progress/planned in Australia and China, both as monotherapy and with combinations (e.g., rapamycin, everolimus)[1][2][3][8].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of New South Wales

Beyond the preview

Go deeper on PENAO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PENAO.

Explore the full profile